- Home
- BVN vs ITGR Comparison
BVN vs ITGR Comparison
Compare BVN & ITGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- ITGR
- Stock Information
- Founded
- BVN 1953
- ITGR 1970
- Country
- BVN Peru
- ITGR United States
- Employees
- BVN N/A
- ITGR N/A
- Industry
- BVN Metal Mining
- ITGR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- BVN Basic Materials
- ITGR Health Care
- Exchange
- BVN Nasdaq
- ITGR Nasdaq
- Market Cap
- BVN 4.2B
- ITGR 4.2B
- IPO Year
- BVN 1996
- ITGR 2000
- Fundamental
- Price
- BVN $17.49
- ITGR $107.00
- Analyst Decision
- BVN Buy
- ITGR Strong Buy
- Analyst Count
- BVN 2
- ITGR 9
- Target Price
- BVN $16.75
- ITGR $141.78
- AVG Volume (30 Days)
- BVN 805.4K
- ITGR 492.0K
- Earning Date
- BVN 07-24-2025
- ITGR 07-24-2025
- Dividend Yield
- BVN 1.67%
- ITGR N/A
- EPS Growth
- BVN 436.33
- ITGR N/A
- EPS
- BVN 1.98
- ITGR 2.31
- Revenue
- BVN $1,307,905,000.00
- ITGR $1,794,800,000.00
- Revenue This Year
- BVN $14.24
- ITGR $10.92
- Revenue Next Year
- BVN $9.63
- ITGR $7.35
- P/E Ratio
- BVN $8.55
- ITGR $46.29
- Revenue Growth
- BVN 32.24
- ITGR 9.64
- 52 Week Low
- BVN $11.50
- ITGR $104.93
- 52 Week High
- BVN $17.98
- ITGR $146.36
- Technical
- Relative Strength Index (RSI)
- BVN 57.38
- ITGR 32.53
- Support Level
- BVN $16.90
- ITGR $105.43
- Resistance Level
- BVN $17.67
- ITGR $110.02
- Average True Range (ATR)
- BVN 0.54
- ITGR 2.93
- MACD
- BVN -0.04
- ITGR -0.59
- Stochastic Oscillator
- BVN 71.88
- ITGR 9.92
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About ITGR Integer Holdings Corporation
Integer Holdings Corp is a manufacturer of medical device components used by original equipment manufacturers in the medical industry. The company also develops batteries used in nonmedical applications in the energy, military, and environmental markets. The firm organizes itself into one segment and derives its revenues from three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation and Other Markets. The company earns more than half of its revenue in the United States.